Ptáková N, et al. - For this investigation, researchers gathered and reviewed all leiomyosarcoma and STUMP cases diagnosed in a 10-year period (2006–2016) at Charles University Faculty of Medicine in Pilsen to explore the value of targeted molecular screening for identifying uterine anaplastic lymphoma kinase (ALK)-rearranged mesenchymal tumors, including ALK immunohistochemistry followed by molecular genetic testing, in all uterine leiomyosarcomas and STUMPs. In identifying uterine IMT cases, inflammatory myofibroblastic tumor (IMT)-like histologic features might not be an early reliable screening tool. In all uterine LMS and STUMP cases, they proposed a two-step IHC and molecular genetic testing for IMT to enhance the proper detection of such tumors at the population level and ultimately offer patients available targeted therapies.